Canine Hemangiosarcoma Treated with Standard Chemotherapy and Minocycline

Elevated serum thymidine kinase activity in canine splenic hemangiosarcoma*

“…splenic, hepatic, cardiac) HSA will present urgently with signs related to tumour rupture and secondary haemorrhage, leading to acute death in some cases. Furthermore, when HSA is treated surgically prior to rupture, there may be a concomitant improvement in outcome with treatment 39,41,42 . Given the clinically occult nature of most visceral HSA prior to rupture, the urgent and life‐threatening presentation of HSA in many cases, and the improvement in prognosis associated with early detection, a novel screening test for canine HSA would have great clinical utility.…”

Continuous Low‐Dose Oral Chemotherapy for Adjuvant Therapy of Splenic Hemangiosarcoma in Dogs

“…7,8 However, neither DOX dose intensification nor addition of minocycline were found to produce significant improvement in overall survival times compared wtih treatment with DOX alone. 7,8 In contrast, a significant improvement in survival was observed in dogs treated with an immune modulator (liposome-encapsulated muramyl tripeptide phosphatidylethanolamine [L-MTP-PE]) combined with chemotherapy (median survival time, 162 days) compared with dogs treated with chemotherapy alone (median survival time, 96 days), but survival times were still relatively short. 9 Thus, there remains a need for improved adjuvant therapy for preventing metastases in dogs with HSA.…”

Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001–2012)

“…Epirubicin, a stereoisomer of doxorubicin developed to reduce cardiotoxicity, also appears to prolong survival time. 20 Studies [6][7][8]10,[12][13][14][15][16][17] reported to date that have investigated the effects of chemotherapy on survival time have consisted of 6 to 34 dogs, and clinical staging systems and the proportions of dogs in each stage have been variable. Evidence also exists that cyclophosphamide-and etoposide-based metronomic chemotherapy (daily oral low-dose chemotherapy) can extend survival time of dogs with splenic hemangiosarcoma.…”